newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

  • Minerva Neurosciences presented clinical data at the 2026 SIRS Annual Congress in Florence, Italy, regarding the co-administration of roluperidone & olanzapine.
  • The open-label safety trial demonstrated no clinically significant adverse effects, pharmacokinetic changes, or pharmacodynamic changes during combined administration.
  • The confirmatory Phase 3 trial is currently enrolling, with topline data anticipated in the second half of 2027.
  • The study findings were presented by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences.